Memphasys Ltd has released a press release.
Vitrolife sign Felix distribution agreement for Japanese mkt
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Memphasys
- Felix considered best method to treat cryopreserved semen
- Japan first commercial sale and first baby born using Felix
- KOL testings demonstrate Felix System outperforms DGC
- FELIX System commercialisation, regulatory plan and trial
- Rights Issue Closure and Shortfall Notification
Later from Memphasys
- Felix System records 10 new live births in India
- Board and executive transition and capital raise
- $4.2m raise to pursue commercial opportunities with Felix
- Vitrolife distribution agreement expands into Canada and NZ
- AI-Port Update - Spring Field Trial Yields Positive Results
Follow Memphasys into a list and get an email when it puts out news.
Follow Memphasys